Transthyretin Amyloidosis Treatment Market Size to Reach USD 14.28 Billion by 2031 Amid Rising Adoption of Disease-Modifying Therapies

Introduction

According to Mordor Intelligence, the transthyretin amyloidosis treatment market size is expected to reach USD 7.05 billion in 2026 and is forecast to grow to USD 14.28 billion by 2031, registering a CAGR of 15.17% during the forecast period. Increasing regulatory approvals for disease-modifying therapies and growing awareness of transthyretin amyloidosis are contributing to market expansion across several healthcare systems.

The transthyretin amyloidosis treatment industry is benefiting from improved diagnostic approaches and broader access to specialized therapies. Healthcare providers are identifying more patients through improved screening programs and updated cardiology guidelines that include amyloidosis markers. Pharmaceutical companies are also increasing investments in stabilizers, silencers, and gene-editing therapies aimed at reducing disease progression and improving patient outcomes.

Report Overview: https://www.mordorintelligence.com/industry-reports/transthyretin-amyloidosis-treatment-market?utm_source=openpr

Transthyretin Amyloidosis Treatment Market Trends

Growing Adoption of Disease-Modifying Therapies

One of the major transthyretin amyloidosis treatment market trends is the increasing use of disease-modifying therapies designed to slow disease progression and reduce cardiovascular complications. Pharmaceutical companies are focusing on therapies that stabilize transthyretin proteins or reduce abnormal protein production.

Increasing Focus on Early Diagnosis and Screening

Another important transthyretin amyloidosis treatment market trend is the growing emphasis on early disease detection. Hospitals and healthcare systems are increasingly using advanced imaging technologies and artificial intelligence-supported screening tools to identify transthyretin amyloidosis at earlier stages.

Expansion of Gene-Based Therapeutic Research

Gene-based treatment approaches are becoming an important area within the transthyretin amyloidosis treatment market forecast. Pharmaceutical companies and biotechnology firms are investing in gene-editing and RNA-targeted therapies aimed at reducing abnormal transthyretin protein production.

Check out more details and stay updated with the latest industry trends, including the Japanese version for localized insights: https://www.mordorintelligence.com/ja/industry-reports/transthyretin-amyloidosis-treatment-market?utm_source=openpr

Transthyretin Amyloidosis Treatment Market Segmentation

By Amyloidosis Type

ATTR-CM

ATTR-PN

Others

By Therapy

Stabilizers

Silencers

Depleters and Transplant

By Disease Type

Wild-type Amyloidosis

Hereditary Amyloidosis

Mixed-phenotype

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Specialty Channels

By Geography

North America

Europe

Asia-Pacific

Middle East and Africa

South America

Explore Our Full Library of Healthcare Research:
https://www.mordorintelligence.com/market-analysis/healthcare?utm_source=openpr

Competitive Landscape in the Transthyretin Amyloidosis Treatment Industry

The transthyretin amyloidosis treatment industry includes pharmaceutical companies and biotechnology firms focused on rare disease therapies, gene-based treatments, and protein stabilization technologies. Companies are investing in clinical development programs, regulatory approvals, and global market expansion strategies to strengthen their position.

Key Players

Pfizer Inc.

Alnylam Pharmaceuticals, Inc.

Intellia Therapeutics, Inc.

AstraZeneca PLC

BridgeBio Pharma Inc

Explore more insights on transthyretin amyloidosis treatment competitive landscape: https://www.mordorintelligence.com/industry-reports/transthyretin-amyloidosis-treatment-market/companies?utm_source=openpr

Conclusion

The transthyretin amyloidosis treatment market is expected to maintain strong momentum as healthcare providers continue improving rare disease diagnosis and treatment access. Increasing awareness, growing availability of disease-modifying therapies, and expanding research activities are supporting long-term market demand.

Pharmaceutical companies are focusing on targeted therapies that address disease progression and improve patient quality of life. The increasing use of advanced screening technologies and earlier diagnosis programs is also helping expand the treated patient population.

The transthyretin amyloidosis treatment market forecast remains positive due to rising investments in rare disease therapies, gene-based treatment research, and global regulatory approvals. As healthcare systems continue emphasizing specialized disease management, the transthyretin amyloidosis treatment industry is expected to remain an important segment within the broader rare disease treatment landscape.

For more insights on the transthyretin amyloidosis treatment, please visit the Mordor Intelligence page: https://www.mordorintelligence.com/industry-reports/transthyretin-amyloidosis-treatment-market?utm_source=openpr

Industry Related Reports

Vitiligo Treatment Market:

The vitiligo treatment market is witnessing steady growth due to increasing prevalence of skin disorders, rising awareness regarding advanced dermatological therapies, and growing demand for minimally invasive treatment options. Advancements in topical therapies, light-based treatments, and aesthetic dermatology are further supporting market expansion globally.

Get more insights: https://www.mordorintelligence.com/industry-reports/vitiligo-treatment-market?utm_source=openpr

Monogenetic Disease Therapy Market size:

The monogenetic disease therapy market is projected to reach USD 60.58 billion by 2030, growing at a CAGR of 10.80% during the forecast period. Increasing adoption of gene therapies, rising investments in precision medicine, and growing focus on rare genetic disorder treatments are driving market growth worldwide.

Get more insights: https://www.mordorintelligence.com/industry-reports/monogenetic-disease-therapy-market?utm_source=openpr

Hereditary Angioedema Therapeutics Market share:

The hereditary angioedema therapeutics market is expected to reach USD 14.69 billion by 2031, registering a CAGR of 16.56% during 2026-2031. Rising awareness regarding rare genetic disorders, increasing availability of targeted therapies, and growing healthcare investments in orphan drug development are fueling market expansion globally.

Get more insights: https://www.mordorintelligence.com/industry-reports/hereditary-angioedema-therapeutics-market?utm_source=openpr

About Mordor Intelligence:

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

Mordor Intelligence, 11th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli, Hyderabad, Telangana - 500032, India.

For any inquiries or to access the full report, please contact:

media@mordorintelligence.com

https://www.mordorintelligence.com/

This release was published on openPR.